Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Mednax

Share:
Related MD
5 Key Reasons To Invest In Mednax
Benzinga's Top Upgrades, Downgrades For September 18, 2017
Handelsinvest Investeringsforvaltning Buys Bank of the Ozarks Inc, Visteon Corp, TPI Composites ... (GuruFocus)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Mednax (NYSE: MD), and raised its price target from $81.00 to $88.00.

Jefferies noted, “MD is one of our top picks given our belief that the company's push to aggressively expand its anesthesiology business (which we expect mgmt to highlight at today's analyst day) will drive robust growth over the next several years that is not yet adequately reflected in the stock's valuation. Our positive bias is also driven by MD's highly defensive (i.e., benign) reimbursement outlook. Reiterate Buy/PT to $88.”

Mednax closed on Tuesday at $75.29.

Latest Ratings for MD

DateFirmActionFromTo
Oct 2017BMO CapitalInitiates Coverage OnMarket Perform
Sep 2017KeyBancUpgradesSector WeightOverweight
Jun 2017Stephens & Co.UpgradesEqual-WeightOverweight

View More Analyst Ratings for MD
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MD)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...